Physician profile
Michael Parks
NPI 1376777847
$19,061.71
in general payments reported to CMS, 2019-2025
13 companies · $156 in 2025
The $156 reported for 2025 was more than what 75% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.17 · 2020: $317 · 2021: $9,474 · 2022: $2,510 · 2023: $4,507 · 2024: $2,074 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $5,700 · Food and Beverage: $841 · Travel and Lodging: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $5,700.00 |
| Food and Beverage | $840.82 |
| Travel and Lodging | $196.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acacia Pharma INC | $11,609.15 | 2021-2022 | |
| Eagle Pharmaceuticals, INC. | $6,254.96 | 2023-2024 | |
| Abbvie INC. | $314.24 | 2022-2025 | |
| Heron Therapeutics, INC. | $240.63 | 2022-2024 | Zynrelef |
| Amgen INC. | $220.60 | 2020 | |
| Ortho Development Corporation | $83.05 | 2020 | |
| Janssen Biotech, INC. | $80.32 | 2024-2025 | Tremfya |
| Pfizer INC. | $63.69 | 2022 | |
| Genzyme Corporation | $50.22 | 2023 | |
| Mindray Ds USA, INC. | $49.97 | 2021 | |
| Merck Sharp & Dohme LLC | $41.59 | 2019-2024 | Bridion |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.33 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $22.96 | 2023 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Parks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.